GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (NAS:SYRS) » Definitions » Equity-to-Asset

Syros Pharmaceuticals (Syros Pharmaceuticals) Equity-to-Asset : 0.10 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Syros Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $16.66 Mil. Syros Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $168.17 Mil. Therefore, Syros Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.10.

The historical rank and industry rank for Syros Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

SYRS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1   Med: 0.63   Max: 0.98
Current: 0.1

During the past 10 years, the highest Equity to Asset Ratio of Syros Pharmaceuticals was 0.98. The lowest was 0.10. And the median was 0.63.

SYRS's Equity-to-Asset is ranked worse than
82.3% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs SYRS: 0.10

Syros Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Syros Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals Equity-to-Asset Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.43 0.47 0.52 0.10

Syros Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.52 0.41 0.25 0.10

Competitive Comparison of Syros Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Syros Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Equity-to-Asset falls into.



Syros Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Syros Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=16.662/168.174
=0.10

Syros Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=16.662/168.174
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syros Pharmaceuticals  (NAS:SYRS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Syros Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Syros Pharmaceuticals (Syros Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is mainly involved in the segments of pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States.
Executives
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
David Roth officer: Chief Medical Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Eric R Olson officer: Chief Scientific Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson director ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Jason Haas officer: Chief Financial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley officer: Chief Commercial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Kristin Stephens officer: Chief Development Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Richard A Young director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn officer: Chief Business Officer C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
Arch Venture Fund Vii, L.p. 10 percent owner 8755 W HIGGINS, SUITE 1025, Chicago IL 60631
Alice Tsang Shaw director MASSACHUSETTS GENERAL HOSPITAL, 55 FRUIT ST., #148, BOSTON MA 02114